Sale

Glaucoma Therapeutics Market

Global Glaucoma Therapeutics Market Size, Growth, Analysis: By Drug Class: Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Others; By Glaucoma Type; By Route of Administration; By Treatment Channel; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Glaucoma Therapeutics Market Outlook

The global glaucoma therapeutics market value in 2023 was USD 6.94 billion driven by the increasing technological advancements in glaucoma diagnosis and treatment across the globe. The market size is anticipated to grow at a CAGR of 5.2% during the forecast period of 2024-2032 to achieve a value of USD 10.96 billion by 2032.

 

glaucoma therapeutics market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

North America to be Among the Significant Regional Markets for Glaucoma Therapeutics

North America is expected to be one of the leading regions in the glaucoma therapeutics market owing to high per capita expenditure on healthcare. Major players operating in the market have made a series of strategic acquisitions, contributing to their market share. Further, the increase in the geriatric population, rise in awareness about glaucoma, availability of reimbursements, and well-established health care infrastructure are the other factors driving the market growth in North America.
 

Europe and the Asia Pacific to Witness Significant Growth

The glaucoma therapeutics market in Europe is expected to increase due to favourable reimbursement policies during the forecast period. Factors contributing to the growth of the market in the region include stronger emphasis by federal governments on improving healthcare facilities and a rise in awareness among the population. On the other hand, the Asia Pacific would showcase the highest growth, fuelled by the increasing ageing population, especially in Japan and China, which require these therapeutics.
 

Market Segmentations

Various therapy options for primary open-angle (POA) and primary angle-closure (PAC) glaucoma are referred to as glaucoma therapeutics. The condition is marked by structural alterations in the optic nerves, resulting in vision loss and blindness. Topical eye drops, which include beta-blockers, prostaglandin analogues, cholinergic, carbonic anhydrase inhibitors, and alpha-adrenergic agonists, can treat glaucoma.

 

glaucoma therapeutics market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

By drug class, the market includes:

  • Prostaglandin Analogues
  • Beta-Blockers
  • Alpha Adrenergic Agonists
  • Carbonic Anhydrase Inhibitors
  • Combination Drugs
  • Others

Based on indication, the market is divided into:

  • Open-Angle Glaucoma
  • Angle Closure Glaucoma
  • Others

The end-uses of the market are:

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgery Centres
  • Others

The regional markets for the glaucoma therapeutics market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

 

glaucoma therapeutics market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Increasing Prevalence of Glaucoma Propelling the Market Growth

One of the major factors driving the market's growth is the rising prevalence of glaucoma across the globe. Glaucoma is quite common among diabetic patients and people with additional visual problems, such as age-related macular degeneration (AMD), cataracts, and dry eye. Following this, the growing geriatric population, which is more vulnerable to such illnesses, propels the market growth. An increase in awareness of glaucoma, medical coverage of glaucoma patients and demand for combination glaucoma drugs are some of the significant trends that can be seen in the global glaucoma therapeutics industry. The industry is also being driven by rising health consciousness among the public and a growing preference for laser glaucoma surgery.

In addition, the invention of unique combination dugs is a growth-stimulating factor. Anti-glaucoma medicines and prostaglandin analogues are being developed by pharmaceutical companies in combination with two or more drugs to lower excessive IOP levels. Other factors, such as the introduction of better glaucoma diagnostic techniques and improvements in healthcare infrastructure, are expected to fuel the market growth further.
 

Key Players in the Global Market for Glaucoma Therapeutics

The report gives a detailed analysis of the following key players in the global glaucoma therapeutics market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Aerie Pharmaceuticals Inc.
  • Bausch & Lomb Incorporated 
  • Inotek Pharmaceuticals Corp.
  • SIFI S.p.A
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Glaucoma Type
  • Route of Administration
  • Treatment Channel
  • End User
  • Distribution Channel
  • Region
Breakup by Drug Class
  • Beta Blockers
  • Prostaglandins
  • Alpha Adrenergic Agonist
  • Carbonic Anhydrase Inhibitors
  • Combination Drugs
  • Others
Breakup by Glaucoma Type
  • Closed Angle Glaucoma (CAG)
  • Open Angle Glaucoma (OAG)
  • Secondary Glaucoma
  • Congenital Glaucoma
  • Others
Breakup by Route of Administration
  • Oral
  • Parentals
  • Topicals
  • Others
Breakup by Treatment Channel
  • Public
  • Private
Breakup by End User
  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Aerie Pharmaceuticals, Inc.
  • Allergan
  • Bausch Health
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Fera Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • EyePoint Pharmaceuticals
  • Amorphex Therapeutics LLC.
  • Acorn Biomedical, Inc.
  • Acucela Inc.
  • Alcon
  • Astellas Pharma Inc.
  • Bayer AG
  • BioAxone
  • Novartis AG
  • Carl Zeiss Meditec
  • Alcon, Lumenis
  • Topcon Medical Systems
  • Accutome
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Glaucoma Diseases Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Glaucoma Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Glaucoma Epidemiology (2016-2031)
    5.3    Europe Glaucoma Epidemiology (2016-2031)
    5.4    Asia-Pacific Glaucoma Epidemiology (2016-2031)
    5.5    Latin America Glaucoma Epidemiology (2016-2031)
    5.6    Middle East & Africa Glaucoma Epidemiology (2016-2031)
6    Global Glaucoma Therapeutics Market Overview
    6.1    Global Glaucoma Therapeutics Market Historical Value (2017-2023) 
    6.2    Global Glaucoma Therapeutics Market Forecast Value (2024-2032)
7    Global Glaucoma Therapeutics Market Landscape
    7.1    Glaucoma Therapeutics: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Glaucoma Therapeutics: Product Landscape
        7.2.1    Analysis by Drug Class
        7.2.2    Analysis by Glaucoma Type
        7.2.3    Analysis by Route of Administration
        7.2.4    Analysis by End User
        7.2.5    Analysis by Distribution Channel
8    Glaucoma Therapeutics Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Glaucoma Therapeutics Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Glaucoma Therapeutics Market Segmentation
    11.1    Global Glaucoma Therapeutics Market by Drug Class
        11.1.1    Market Overview
        11.1.2    Beta Blockers
        11.1.3    Prostaglandins
        11.1.4    Alpha Adrenergic Agonist
        11.1.5    Carbonic Anhydrase Inhibitors
        11.1.6    Combination Drugs
        11.1.7    Others
    11.2    Global Glaucoma Therapeutics Market by Glaucoma Type
        11.2.1    Market Overview
        11.2.2    Closed Angle Glaucoma (CAG)
        11.2.3    Open Angle Glaucoma (OAG)
        11.2.4    Secondary Glaucoma
        11.2.5    Congenital Glaucoma
        11.2.6    Others
    11.3    Global Glaucoma Therapeutics Market by Route of Administration
        11.3.1    Market Overview
        11.3.2    Oral 
        11.3.3    Parentals
        11.3.4    Topicals
        11.3.5    Others
    11.4    Global Glaucoma Therapeutics Market by Treatment Channel
        11.4.1    Market Overview
        11.4.2    Public
        11.4.3    Private
    11.5    Global Glaucoma Therapeutics Market by End User
        11.5.1    Market Overview
        11.5.2    Hospitals
        11.5.3    Specialty Clinics
        11.5.4    Homecare Settings
        11.5.5    Others
    11.6    Global Glaucoma Therapeutics Market by Distribution Channel
        11.6.1    Market Overview
        11.6.2    Hospital Pharmacy
        11.6.3    Retail Pharmacy
        11.6.4    Online Pharmacy
        11.6.5    Others
    11.7    Global Glaucoma Therapeutics Market by Region
        11.7.1    Market Overview
        11.7.2    North America
        11.7.3    Europe 
        11.7.4    Asia Pacific
        11.7.5    Latin America
        11.7.6    Middle East and Africa
12    North America Glaucoma Therapeutics Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Glaucoma Therapeutics Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Glaucoma Therapeutics Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Glaucoma Therapeutics Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Glaucoma Therapeutics Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Aerie Pharmaceuticals, Inc.
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Allergan
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Bausch Health
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Merck & Co. Inc.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Pfizer Inc.
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Fera Pharmaceuticals
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Teva Pharmaceutical Industries Ltd.
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    EyePoint Pharmaceuticals
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Amorphex Therapeutics LLC.
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Acorn Biomedical, Inc.
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Acucela Inc.
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12    Alcon
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications
    23.13    Astellas Pharma Inc.
        23.13.1    Financial Analysis
        23.13.2    Product Portfolio
        23.13.3    Demographic Reach and Achievements
        23.13.4    Mergers and Acquisitions
        23.13.5    Certifications
    23.14    Bayer AG
        23.14.1    Financial Analysis
        23.14.2    Product Portfolio
        23.14.3    Demographic Reach and Achievements
        23.14.4    Mergers and Acquisitions
        23.14.5    Certifications
    23.15    BioAxone
        23.15.1    Financial Analysis
        23.15.2    Product Portfolio
        23.15.3    Demographic Reach and Achievements
        23.15.4    Mergers and Acquisitions
        23.15.5    Certifications
    23.16    Novartis AG
        23.16.1    Financial Analysis
        23.16.2    Product Portfolio
        23.16.3    Demographic Reach and Achievements
        23.16.4    Mergers and Acquisitions
        23.16.5    Certifications
    23.17    Carl Zeiss Meditec
        23.17.1    Financial Analysis
        23.17.2    Product Portfolio
        23.17.3    Demographic Reach and Achievements
        23.17.4    Mergers and Acquisitions
        23.17.5    Certifications
    23.18    Alcon, Lumenis
        23.18.1    Financial Analysis
        23.18.2    Product Portfolio
        23.18.3    Demographic Reach and Achievements
        23.18.4    Mergers and Acquisitions
        23.18.5    Certifications
    23.19    Topcon Medical Systems
        23.19.1    Financial Analysis
        23.19.2    Product Portfolio
        23.19.3    Demographic Reach and Achievements
        23.19.4    Mergers and Acquisitions
        23.19.5    Certifications
    23.20    Accutome
        23.20.1    Financial Analysis
        23.20.2    Product Portfolio
        23.20.3    Demographic Reach and Achievements
        23.20.4    Mergers and Acquisitions
        23.20.5    Certifications
24    Glaucoma Therapeutics Market- Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

Globally, glaucoma therapeutics market reached a value of USD 6.94 billion in 2023.

The market is projected to expand at a CAGR of 5.2% from 2024 to 2032, growing to USD 10.96 billion by 2032.

The major drivers of the market include favourable reimbursement policies, an increase in awareness of glaucoma, rising health consciousness, the invention of unique combination drugs, the introduction of better glaucoma diagnostic techniques and improvements in healthcare infrastructure.

The rising prevalence of glaucoma around the world and the growing geriatric population are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Based on drug class, the market includes prostaglandin analogues, beta-blockers, alpha-adrenergic agonists, carbonic anhydrase inhibitors, and combination drugs, among others.

The various indications of the market are open-angle glaucoma and angle-closure glaucoma, among others.

The end-uses of the market are hospitals, ophthalmic clinics, and ambulatory surgery centres, among others.

The major players in the industry are Aerie Pharmaceuticals Inc., Bausch & Lomb Incorporated, Inotek Pharmaceuticals Corp., SIFI S.p.A, Viatris Inc., and Teva Pharmaceutical Industries Ltd., among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER